Roswell Park Cancer Institute (RPCI) was established in 1898 on the principle of integrating clinical cancer care, cancer research and cancer education. Since then, groundbreaking research by RPCI scientists has led to greater understanding of the nature of cancer and to major advances in cancer diagnosis and treatment.

RPCI instituted the nation's first chemotherapy program, pioneered studies on the relationship between smoking and lung cancer and developed photodynamic therapy (PDT) and the prostate-specific antigen (PSA) blood test. RPCI is the only upstate New York facility to hold the National Cancer Institute designation of "comprehensive cancer center" and one of 41 such centers in the United States. This designation means that a cancer center's combined research, treatment and educational programs have weathered extensive peer review, met rigorous national standards, and made fundamental contributions to reducing the cancer burden.

Roswell Park clinicians and researchers work to quickly answer questions about the cause of cancer and the effectiveness of potential therapies by working together on key programs. While a great deal of collaboration exists among investigators in all disciplines, there are six major research programs at RPCI, each with well-defined missions, themes, goals, and investigative mechanisms. These programs also incorporate the expertise of clinical researchers within the departments of medicine, surgery, radiation medicine and pathology and the subspecialty services, and provide a forum in which to explore translational projects in specific cancers and to collaborate and explore new concepts in treatment for these diseases. While RPCI has significant strengths in translational research, the physician scientist is uniquely positioned to bridge the gap between the laboratory and the clinic.

Learn more about Roswell Park Cancer Institute and our research here.